SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0000950170-24-059596
Filing Date
2024-05-14
Accepted
2024-05-14 16:20:33
Documents
39
Period of Report
2024-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q evok-20240331.htm   iXBRL 10-Q 811067
2 EX-31.1 evok-ex31_1.htm EX-31.1 13162
3 EX-32.1 evok-ex32_1.htm EX-32.1 8775
4 GRAPHIC img216179745_0.jpg GRAPHIC 194720
  Complete submission text file 0000950170-24-059596.txt   4054832

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT evok-20240331.xsd EX-101.SCH 676514
42 EXTRACTED XBRL INSTANCE DOCUMENT evok-20240331_htm.xml XML 448182
Mailing Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075
Business Address 420 STEVENS AVENUE SUITE 370 SOLANA BEACH CA 92075 858-345-1494
Evoke Pharma Inc (Filer) CIK: 0001403708 (see all company filings)

IRS No.: 208447886 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-36075 | Film No.: 24944677
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)